Private placement yields $2.5 million from the sale of Veris Health common stock at a $35 million pre-money valuation. NEW YORK, June 24, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary, Veris Health Inc. ("Veris"), today announced the completion of a private placement equity financing directly into Veris, yielding ...

Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – JamesNEW YORK, June 3, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris has entered into a strategic ...

Core Insights - American Oncology Network (AON) is expanding access to radioligand therapies (RLT) for prostate and neuroendocrine cancers, reflecting a commitment to innovative cancer care [1][5] - Over 300 treatments have been administered to nearly 70 patients across five AON partner practices, indicating strong demand and success for these therapies [1][5] Company Overview - AON is a rapidly growing community oncology network founded in 2018, representing over 290 providers across 21 states [6] - The organization focuses on value-based care, improving patient outcomes while reducing costs and expanding access to quality care [6] - AON aims to promote health equity by addressing disparities in cancer care and ensuring all patients have access to necessary treatments [6] Radioligand Therapies - AON now offers three FDA-approved radiopharmaceuticals: Pluvicto™, Xofigo, and Lutathera, targeting specific cancer types [2][3] - Radioligand therapy involves attaching a radioactive isotope to a targeting molecule, allowing for precise radiation delivery to cancer cells while minimizing damage to healthy tissue [2][3] Future Growth - AON anticipates continued growth in the utilization of radioligand therapies as more sites obtain the necessary infrastructure and regulatory approvals [5]